Proactiveinvestors USA & Canada BioPorto https://ca.proactiveinvestors.com Proactiveinvestors USA & Canada BioPorto RSS feed en Sun, 29 Nov 2020 00:45:49 -0500 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) BioPorto maintains sales momentum of NGAL test, begins patient enrollment for coronavirus test https://ca.proactiveinvestors.com/companies/news/934443/bioporto-maintains-sales-momentum-of-ngal-test-begins-patient-enrollment-for-coronavirus-test-934443.html Thu, 19 Nov 2020 15:46:00 -0500 https://ca.proactiveinvestors.com/companies/news/934443/bioporto-maintains-sales-momentum-of-ngal-test-begins-patient-enrollment-for-coronavirus-test-934443.html BioPorto Diagnostics A/S is helping develop a ten-minute coronavirus test that could be on the market by the year-end https://ca.proactiveinvestors.com/companies/news/931948/bioporto-diagnostics-as-is-helping-develop-a-ten-minute-coronavirus-test-that-could-be-on-the-market-by-the-year-end-931948.html Tue, 20 Oct 2020 16:44:00 -0400 https://ca.proactiveinvestors.com/companies/news/931948/bioporto-diagnostics-as-is-helping-develop-a-ten-minute-coronavirus-test-that-could-be-on-the-market-by-the-year-end-931948.html BioPorto Diagnostics reveals progress on its co-developed 10-minute coronavirus test https://ca.proactiveinvestors.com/companies/news/929465/bioporto-diagnostics-reveals-progress-on-its-co-developed-10-minute-coronavirus-test-929465.html Fri, 18 Sep 2020 15:26:00 -0400 https://ca.proactiveinvestors.com/companies/news/929465/bioporto-diagnostics-reveals-progress-on-its-co-developed-10-minute-coronavirus-test-929465.html BioPorto and University of Southern Denmark make progress on 10-minute coronavirus test https://ca.proactiveinvestors.com/companies/news/929380/bioporto-and-university-of-southern-denmark-make-progress-on-10-minute-coronavirus-test-929380.html Thu, 17 Sep 2020 16:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/929380/bioporto-and-university-of-southern-denmark-make-progress-on-10-minute-coronavirus-test-929380.html BioPorto reveals another quarter of strong revenue from sales of its NGAL kidney damage test https://ca.proactiveinvestors.com/companies/news/927502/bioporto-reveals-another-quarter-of-strong-revenue-from-sales-of-its-ngal-kidney-damage-test-927502.html Tue, 25 Aug 2020 14:34:00 -0400 https://ca.proactiveinvestors.com/companies/news/927502/bioporto-reveals-another-quarter-of-strong-revenue-from-sales-of-its-ngal-kidney-damage-test-927502.html BioPorto focused on flagship NGAL acute kidney-injury test but also looking at coronavirus test https://ca.proactiveinvestors.com/companies/news/219607/bioporto-focused-on-flagship-ngal-acute-kidney-injury-test-but-also-looking-at-coronavirus-test-219607.html Fri, 21 Aug 2020 11:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/219607/bioporto-focused-on-flagship-ngal-acute-kidney-injury-test-but-also-looking-at-coronavirus-test-219607.html BioPorto sees revenue from its NGAL kidney test nearly double in second-quarter 2020 https://ca.proactiveinvestors.com/companies/news/927072/bioporto-sees-revenue-from-its-ngal-kidney-test-nearly-double-in-second-quarter-2020-927072.html Wed, 19 Aug 2020 14:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/927072/bioporto-sees-revenue-from-its-ngal-kidney-test-nearly-double-in-second-quarter-2020-927072.html BioPorto begins enrolling in its clinical study to treat children with severe acute kidney injury https://ca.proactiveinvestors.com/companies/news/922767/bioporto-begins-enrolling-in-its-clinical-study-to-treat-children-with-severe-acute-kidney-injury-922767.html Thu, 25 Jun 2020 13:21:00 -0400 https://ca.proactiveinvestors.com/companies/news/922767/bioporto-begins-enrolling-in-its-clinical-study-to-treat-children-with-severe-acute-kidney-injury-922767.html BioPorto enrolls first patients in US paediatric study of NGAL; on track for FDA submission in 2020 https://ca.proactiveinvestors.com/companies/news/922896/bioporto-enrolls-first-patients-in-us-paediatric-study-of-ngal-on-track-for-fda-submission-in-2020-922896.html Tue, 23 Jun 2020 16:49:00 -0400 https://ca.proactiveinvestors.com/companies/news/922896/bioporto-enrolls-first-patients-in-us-paediatric-study-of-ngal-on-track-for-fda-submission-in-2020-922896.html BioPorto in partnership awarded US$400K to test if Iloprost can improve coronavirus survival rates https://ca.proactiveinvestors.com/companies/news/919631/bioporto-in-partnership-awarded-us400k-to-test-if-iloprost-can-improve-coronavirus-survival-rates-919631.html Thu, 14 May 2020 15:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/919631/bioporto-in-partnership-awarded-us400k-to-test-if-iloprost-can-improve-coronavirus-survival-rates-919631.html BioPorto sees a 67% increase in NGAL-related revenue in its first quarter https://ca.proactiveinvestors.com/companies/news/919297/bioporto-sees-a-67-increase-in-ngal-related-revenue-in-its-first-quarter-919297.html Mon, 11 May 2020 14:58:00 -0400 https://ca.proactiveinvestors.com/companies/news/919297/bioporto-sees-a-67-increase-in-ngal-related-revenue-in-its-first-quarter-919297.html BioPorto says proprietary NGAL test helps boost 1Q revenue by double-digits https://ca.proactiveinvestors.com/companies/news/919092/bioporto-says-proprietary-ngal-test-helps-boost-1q-revenue-by-double-digits-919092.html Thu, 07 May 2020 13:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/919092/bioporto-says-proprietary-ngal-test-helps-boost-1q-revenue-by-double-digits-919092.html BioPorto Diagnostics developing test to detect coronavirus in less than 10 minutes https://ca.proactiveinvestors.com/companies/news/917432/bioporto-diagnostics-developing-test-to-detect-coronavirus-in-less-than-10-minutes-917432.html Thu, 16 Apr 2020 13:56:00 -0400 https://ca.proactiveinvestors.com/companies/news/917432/bioporto-diagnostics-developing-test-to-detect-coronavirus-in-less-than-10-minutes-917432.html BioPorto and University of Southern Denmark fast-track development of test to detect coronavirus in less than 10 minutes https://ca.proactiveinvestors.com/companies/news/916372/bioporto-and-university-of-southern-denmark-fast-track-development-of-test-to-detect-coronavirus-in-less-than-10-minutes-916372.html Wed, 01 Apr 2020 13:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/916372/bioporto-and-university-of-southern-denmark-fast-track-development-of-test-to-detect-coronavirus-in-less-than-10-minutes-916372.html BioPorto revises subscription price for its intended rights issue https://ca.proactiveinvestors.com/companies/news/915116/bioporto-revises-subscription-price-for-its-intended-rights-issue-915116.html Tue, 17 Mar 2020 12:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/915116/bioporto-revises-subscription-price-for-its-intended-rights-issue-915116.html BioPorto launches rights issue to boost financial position amid coronavirus outbreak https://ca.proactiveinvestors.com/companies/news/914780/bioporto-launches-rights-issue-to-boost-financial-position-amid-coronavirus-outbreak-914780.html Wed, 11 Mar 2020 16:50:00 -0400 https://ca.proactiveinvestors.com/companies/news/914780/bioporto-launches-rights-issue-to-boost-financial-position-amid-coronavirus-outbreak-914780.html BioPorto pushes ahead with development of flagship kidney disease test NGAL https://ca.proactiveinvestors.com/companies/news/914773/bioporto-pushes-ahead-with-development-of-flagship-kidney-disease-test-ngal-914773.html Wed, 11 Mar 2020 15:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/914773/bioporto-pushes-ahead-with-development-of-flagship-kidney-disease-test-ngal-914773.html BioPorto expects revenue of US$4.3M in 2020 on increased NGAL Test sales https://ca.proactiveinvestors.com/companies/news/913749/bioporto-expects-revenue-of-us43m-in-2020-on-increased-ngal-test-sales-913749.html Wed, 26 Feb 2020 14:59:00 -0500 https://ca.proactiveinvestors.com/companies/news/913749/bioporto-expects-revenue-of-us43m-in-2020-on-increased-ngal-test-sales-913749.html BioPorto's 3Q revenue increases 24% year-over-year https://ca.proactiveinvestors.com/companies/news/907576/bioporto-s-3q-revenue-increases-24-year-over-year-907576.html Thu, 21 Nov 2019 15:18:00 -0500 https://ca.proactiveinvestors.com/companies/news/907576/bioporto-s-3q-revenue-increases-24-year-over-year-907576.html BioPorto to provide additional patient data to back FDA application for NGAL test https://ca.proactiveinvestors.com/companies/news/907305/bioporto-to-provide-additional-patient-data-to-back-fda-application-for-ngal-test-907305.html Mon, 18 Nov 2019 20:07:00 -0500 https://ca.proactiveinvestors.com/companies/news/907305/bioporto-to-provide-additional-patient-data-to-back-fda-application-for-ngal-test-907305.html BioPorto sees boost in revenue in second quarter https://ca.proactiveinvestors.com/companies/news/900896/bioporto-sees-boost-in-revenue-in-second-quarter-900896.html Thu, 15 Aug 2019 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/900896/bioporto-sees-boost-in-revenue-in-second-quarter-900896.html BioPorto reveals 'healthy growth' in second quarter revenue https://ca.proactiveinvestors.com/companies/news/900875/bioporto-reveals--healthy-growth--in-second-quarter-revenue-900875.html Thu, 15 Aug 2019 14:33:00 -0400 https://ca.proactiveinvestors.com/companies/news/900875/bioporto-reveals--healthy-growth--in-second-quarter-revenue-900875.html BioPorto optimistic over FDA clearance for its NGAL kidney diagnostic test for use on children https://ca.proactiveinvestors.com/companies/news/314284/bioporto-optimistic-over-fda-clearance-for-its-ngal-kidney-diagnostic-test-for-use-on-children-14284.html Wed, 31 Jul 2019 17:09:00 -0400 https://ca.proactiveinvestors.com/companies/news/314284/bioporto-optimistic-over-fda-clearance-for-its-ngal-kidney-diagnostic-test-for-use-on-children-14284.html BioPorto completes private placing, raising around US$5.5M net https://ca.proactiveinvestors.com/companies/news/223074/bioporto-completes-private-placing-raising-around-us55m-net-223074.html Fri, 28 Jun 2019 15:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/223074/bioporto-completes-private-placing-raising-around-us55m-net-223074.html Diagnostic company BioPorto taps Christopher Bird as chief medical officer https://ca.proactiveinvestors.com/companies/news/222871/diagnostic-company-bioporto-taps-christopher-bird-as-chief-medical-officer-222871.html Wed, 26 Jun 2019 14:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/222871/diagnostic-company-bioporto-taps-christopher-bird-as-chief-medical-officer-222871.html BioPorto private placement of more than 9.2 million shares fully subscribed https://ca.proactiveinvestors.com/companies/news/222269/bioporto-private-placement-of-more-than-92-million-shares-fully-subscribed-222269.html Mon, 17 Jun 2019 19:54:00 -0400 https://ca.proactiveinvestors.com/companies/news/222269/bioporto-private-placement-of-more-than-92-million-shares-fully-subscribed-222269.html BioPorto submits kidney-injury test in children to FDA https://ca.proactiveinvestors.com/companies/news/313560/bioporto-submits-kidney-injury-test-in-children-to-fda-13560.html Mon, 03 Jun 2019 12:56:00 -0400 https://ca.proactiveinvestors.com/companies/news/313560/bioporto-submits-kidney-injury-test-in-children-to-fda-13560.html BioPorto submits FDA application for approval of its proprietary kidney-injury test for use in children https://ca.proactiveinvestors.com/companies/news/220338/bioporto-submits-fda-application-for-approval-of-its-proprietary-kidney-injury-test-for-use-in-children-220338.html Wed, 15 May 2019 14:16:00 -0400 https://ca.proactiveinvestors.com/companies/news/220338/bioporto-submits-fda-application-for-approval-of-its-proprietary-kidney-injury-test-for-use-in-children-220338.html BioPorto's 1Q revenue increases 20% partly on sales of its flagship NGAL Test https://ca.proactiveinvestors.com/companies/news/219991/bioporto-s-1q-revenue-increases-20-partly-on-sales-of-its-flagship-ngal-test-219991.html Thu, 09 May 2019 14:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/219991/bioporto-s-1q-revenue-increases-20-partly-on-sales-of-its-flagship-ngal-test-219991.html BioPorto reports 20% increase in revenue growth for 1Q https://ca.proactiveinvestors.com/companies/news/313281/bioporto-reports-20-increase-in-revenue-growth-for-1q-13281.html Thu, 09 May 2019 14:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/313281/bioporto-reports-20-increase-in-revenue-growth-for-1q-13281.html